Exploiting the different mechanisms that impair T cell response, co-blockade of CTLA-4 and PD-1 (Ipilimumab + Nivolumab) revealed additional anti-tumor efficacy but also high levels of side effects in treatment of melanoma (136). This evidence concerns the gene CTLA4 and neoplasm.